The Epigenetic Regulatory Protein CBX2 Promotes mTORC1 Signalling and Inhibits DREAM Complex Activity to Drive Breast Cancer Cell Growth
Bilton, Lucie J.; Warren, Chloe; Humphries, Rebecca M.; Kalsi, Shannon; Waters, Ella; Francis, Thomas; Dobrowinski, Wojtek; Beltran-Alvarez, Pedro; Wade, Mark A.
Authors
Lucie J. Bilton
Chloe Warren
Rebecca M. Humphries
Shannon Kalsi
Ella Waters
Thomas Francis
Wojtek Dobrowinski
Dr Pedro Beltran-Alvarez P.Beltran-Alvarez@hull.ac.uk
Senior Lecturer in Health and Climate Change and Programme co-Director of the MSc Health and Climate Change
Dr Mark Wade M.Wade@hull.ac.uk
Senior Lecturer in Molecular Genetics
Abstract
Chromobox 2 (CBX2) is a chromatin-binding component of polycomb repressive complex 1, which causes gene silencing. CBX2 expression is elevated in triple-negative breast cancer (TNBC), for which there are few therapeutic options. Here, we aimed to investigate the functional role of CBX2 in TNBC. CBX2 knockdown in TNBC models reduced cell numbers, which was rescued by ectopic expression of wild-type CBX2 but not a chromatin binding-deficient mutant. Blocking CBX2 chromatin interactions using the inhibitor SW2_152F also reduced cell growth, suggesting CBX2 chromatin binding is crucial for TNBC progression. RNA sequencing and gene set enrichment analysis of CBX2-depleted cells identified downregulation of oncogenic signalling pathways, including mTORC1 and E2F signalling. Subsequent analysis identified that CBX2 represses the expression of mTORC1 inhibitors and the tumour suppressor RBL2. RBL2 repression, in turn, inhibits DREAM complex activity. The DREAM complex inhibits E2F signalling, causing cell senescence; therefore, inhibition of the DREAM complex via CBX2 may be a key oncogenic driver. We observed similar effects in oestrogen receptor-positive breast cancer, and analysis of patient datasets suggested CBX2 inhibits RBL2 activity in other cancer types. Therapeutic inhibition of CBX2 could therefore repress mTORC1 activation and promote DREAM complex-mediated senescence in TNBC and could have similar effects in other cancer types.
Citation
Bilton, L. J., Warren, C., Humphries, R. M., Kalsi, S., Waters, E., Francis, T., Dobrowinski, W., Beltran-Alvarez, P., & Wade, M. A. (2022). The Epigenetic Regulatory Protein CBX2 Promotes mTORC1 Signalling and Inhibits DREAM Complex Activity to Drive Breast Cancer Cell Growth. Cancers, 14(14), Article 3491. https://doi.org/10.3390/cancers14143491
